Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2012 financial results and reviewed the highlights of the year.  Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year.  For the year ended December 31, 2012, Isis had an NOL of $60.4 million compared to $61.3 million for 2011.  Isis added a substantial amount of cash to its balance sheet throughout 2012, ending the year with nearly $375 million.  On a GAAP basis, Isis reported a loss from operations of $26.1 million and $68.9 million for the three and twelve months ended December 31, 2012, respectively, compared to $18.6 million and $71.1 million for the same periods in 2011. 

"Last month the FDA approved KYNAMRO™.  KYNAMRO is the first systemic antisense drug to be sold commercially.  This is an important event for patients with homozygous familial hypercholesterolemia, for Isis, and for our antisense technology.  KYNAMRO's approval for chronic use in patients who have a severe and fatal disease highlights the potential of our technology to create drugs that could provide benefit for patients," said B. Lynne Parshall, chief operating officer of Isis.  "In addition to KYNAMRO, we have a number of promising new drugs that will report later-stage clinical data this year, setting us up for an exciting year of pipeline activity."

"2012 was a strong year for Isis.  We begin 2013 in a significantly improved financial position with nearly $375 million in cash.  Since the beginning of 2013, we have already received a $25 million milestone payment from Genzyme and a $7.5 million milestone payment from GSK.  With the commercial launch of KYNAMRO and a maturing pipeline of drugs, we have many
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
6. Kewaunee Scientific Reports Improved Results for Third Quarter
7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
8. Questcor Reports Fourth Quarter and Full Year 2012 Results
9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in Boston.  The public is welcome to ... the Array BioPharma website.Event: Wells Fargo Securities Healthcare ... September 10, 2015Time:  , 10:20 a.m. Eastern Time ...
(Date:9/2/2015)... 2, 2015 About Chronic Lymphocytic Leukemia ... characterized by increased production of lymphocytes. It has been ... it can spread to other parts of the body. ... of the slow buildup of the cancerous cells. During ... the spleen, liver, and lymph nodes. The course of ...
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye, today announced that its Board of Directors has ... Mr. Wall was formerly the General Counsel ... firm, for more than nine years. Mr. Wall is currently ... the Corporate Governance Committee and member of the Audit Committee, ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... Md., Nov. 28, 2011 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today that ... present at the Piper Jaffray 23rd Annual Healthcare Conference ... Richman will also be available to participate in one-on-one ...
... Conn., Nov. 28, 2011 Gaylord Sleep Medicine now ... their Glastonbury, Guilford, North Haven and Trumbull locations. ... new Sleep Apnea Management program has expanded to offer ... patient needs. Originally designed to improve PAP compliance, the ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2Gaylord Sleep Medicine Expands Sleep Apnea Management Program 2
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
(Date:9/3/2015)... ... September 03, 2015 , ... Fashion designer Kim (29 ... of the most recent episode of the hit ABC series “Extreme Weight Loss” ... image of her industry. She provided herself with the motivation to transform when she ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... by the Military Officers Association of America (MOAA) and Wounded Warrior Project® ... Caring For Our Own,” expert panelists will lead interactive discussions on the ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3
... , DES MOINES, Iowa, July 10 The "Help is ... the week of July 13 - 16 at various cities ... on programs that provide prescription medicines for free or nearly ... compared to 3.7 percent a year ago, the Partnership for ...
... , NEW YORK, July 10, 2009 Forest ... its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, ... that they have entered into a settlement ... a reference that includes its 100% subsidiaries) and ...
... Va., July 10 The American Physical Therapy Association (APTA) is ... to be properly assessed and fitted by a physical therapist to ... published in the Journal of the American Geriatrics Society ... emergency rooms each year due to falls from improper use and ...
... DENVER, July 10 Cochlear Americas announced today that ... the Cochlear(TM) Baha(R) BP100 Sound Processor, the industry,s first ... an excellent choice for many children and adults with ... deafness. , , The Baha BP100 improves ...
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... damage during play, study finds , FRIDAY, July 10 ... before the season starts may predict the player,s chance ... , Such knowledge could help the pitcher avert ... said. , A five-year study of 144 professional baseball ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 4Health News:Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation 2Health News:Physical Therapists Say Proper Fit and Use of Walkers and Canes Can Prevent Fall-Related Injuries in Elderly 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 3Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Rad-9™...
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
Halogen-free immersion oil based on ester oil....
Medicine Products: